

**IN THE SPECIFICATION:**

Kindly amend the specification as follows:

Kindly amend the paragraph commencing on Page 5, Line 6 as follows:

[[I]] In one embodiment of the invention, a compound, or a mixture of compounds, selected from the group comprising antioxidants, acetylcholine enhancers, trace metals, prosthetic groups and clioquinol, is administered prior to, together with or subsequent to the administration of phanquinone.

Kindly amend the paragraph commencing on Page 5, Line 19 as follows:

The antioxidant is preferably vitamin C, vitamin E, Q10, or combinations thereof. The acetylcholine enhancers are preferable [[ $\mu$ 1]] agonists or anticholinesterase ~~inhibitors~~ inhibitors. Preferred anticholinesterase inhibitors are tacrine (trademark: Cognex) and donepezil (trademark: Aricept). The prosthetic group is preferably vitamin B<sub>12</sub>.

Kindly amend the paragraph commencing on Page 13, Line 22 as follows:

In general, a suitable therapeutically effective amount of phanquinone in the pharmaceutical composition is, for example, 5 to 250 mg, preferably 10 to 50 mg. A suitable amount a compound, or a mixture of compounds, selected from the group comprising antioxidants, [[ $\mu$ 1]] agonists, anticholinesterase inhibitors, trace metals, prosthetic groups and clioquinol in the pharmaceutical composition is, for example, 5  $\mu$ g to 250 mg, preferably 0.5 to 1 mg. If clioquinol and vitamin B<sub>12</sub> is selected, the amount of clioquinol preferably is effective to the treatment or prevention of Alzheimer's disease and the amount of vitamin B<sub>12</sub> is preferably effective to inhibit a detrimental side effect of clioquinol administration. The amounts of clioquinol and vitamin B<sub>12</sub> are preferably 5 mg to 250 mg, most preferred 10 mg to 50 mg and 5 $\mu$  to 2 mg, most preferred [[0,5]] 0.5 mg to 1 mg, respectively.